$BFRI News

Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3

Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Reports Q1 2026 Revenue and EPS Miss, Stock Falls in Pre-Market

Transcript: Biofrontera Q1 2026 Earnings Conference Call

Biofrontera Q1 EPS $(0.41) Misses $(0.12) Estimate, Sales $10.084M Miss $10.250M Estimate

Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate

Biofrontera Inc. Q4 2025 Earnings Call Summary

Biofrontera (BFRI) Q4 2025 Earnings Transcript

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

Biofrontera Inc. Reports Positive Phase 2b Results For Acne Vulgaris Treatment Ameluz Photodynamic Therapy

Biofrontera Inc. Reports Positive Phase 2b Results For Acne Vulgaris Treatment Ameluz Photodynamic Therapy

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

Biofrontera Announces US Patent Trial And Appeal Board Final Written Decision Finding All Challenged Claims Of Sun Pharma's '028 Patent To Be Unpatentable

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Biofrontera Application For Ameluz Usage In Basal Cell Carcinoma Treatment Received By FDA